-
Jan 20, 2025 | 
arrhythmiaacademy.com | Gi-Byoung Nam |Walid Saliba |Oussama Wazni |Manesh R. Patel
AF Symposium 25 - Left atrial appendage (LAA) closure using the WATCHMAN FLX device (Boston Scientific) showed lower risk of bleeding and non-inferiority in efficacy endpoints to oral anticoagulation in patients who have received or are planning to receive AF ablation.
-
Sep 3, 2024 | 
reachmd.com | Gi-Byoung Nam
This summary is based on the presentation of Gi-Byoung Nam , MD, PhD (Seoul, Republic of Korea) at the ESC Congress 2024 - EPIC-CAD - Edoxaban monotherapy vs. dual antithrombotic therapy for atrial fibrillation and stable coronary artery disease. Introduction and methodsPatients with AF and concomitant coronary artery disease (CAD) require anticoagulation treatment to prevent thromboembolic events and antiplatelet therapy to avoid ischemic events.
-
Sep 2, 2024 | 
radcliffecardiology.com | Gi-Byoung Nam |Mirvat Alasnag |Rhian M. Touyz |Vijay Kunadian
Video Published: Views: 7 Likes: 0 Average (ratings) ESC Congress 2024 — Dr Rhian Touyz (McGill University Health Center, CA) joins us to discuss key highlights from the ESC 2024 guidelines for the management of elevated blood pressure and hypertension.
-
Sep 2, 2024 | 
radcliffecardiology.com | Gi-Byoung Nam |Harriette Van Spall |Mirvat Alasnag |Dirk-Jan Van Ginkel
ESC Congress 2024 — No benefit of continuing oral anticoagulation during TAVI procedure. Investigator, Dr Dirk-Jan van Ginkel (St Antonius Hospital, NL) joins us to discuss the result of the POPular PAUSE TAVI trial (NCT04437303; St Antonius Hospital).
-
Sep 2, 2024 | 
radcliffecardiology.com | Gi-Byoung Nam |Harriette Van Spall |Rick A Veasey |Dipak Kotecha
ESC Congress 24 — SHAM-PVI study finds pulmonary vein isolation effective in reducing atrial fibrillation (AF) episodes, improving quality of life. We are joined onsite by Dr Rick Veasey (Eastbourne District General Hospital, Eastbourne, UK) to discuss the findings from a SHAM-PVI, a randomized sham-controlled study of pulmonary vein isolation in symptomatic atrial fibrillation (NCT04272762; East Sussex Hospitals NHS Trust).
-
Sep 1, 2024 | 
radcliffecardiology.com | Gi-Byoung Nam |Harriette Van Spall |Manesh R. Patel |Byoung Geol Choi
ESC Congress 2024 — OCEANIC-AF was halted early due to a lack of efficacy in 2023. Investigators shared details of the trial at ESC, comparing asundexian against apixaban in patients with atrial fibrillation at risk of stroke. Host Dr Harriette Van Spall (McMaster University, Hamilton, Canada) sits down with primary investigator Dr Manesh R Patel (Duke University Health System, USA) to discuss the much-anticipated data from the OCEANIC-AF trial (NCT05643573; Bayer).
-
Sep 1, 2024 | 
nejm.org | Gi-Byoung Nam |Duk-Woo Park
Published September 1, 2024DOI: 10.1056/NEJMoa2407362 For permission requests, please contact NEJM Reprints at [email protected] NotesThis article was published on September 1, 2024, at NEJM.org. A data sharing statement provided by the authors is available with the full text of this article at NEJM.org. Supported by the CardioVascular Research Foundation, Daiichi Sankyo, and Daewoong Pharmaceutical.
-
Sep 1, 2024 | 
nejm.org | Gi-Byoung Nam |Duk-Woo Park
Published September 1, 2024 For permission requests, please contact NEJM Reprints at [email protected] NotesThis article was published on September 1, 2024, at NEJM.org. A data sharing statement provided by the authors is available with the full text of this article at NEJM.org. Supported by the CardioVascular Research Foundation, Daiichi Sankyo, and Daewoong Pharmaceutical. Disclosure forms provided by the authors are available with the full text of this article at NEJM.org.
-
Sep 1, 2024 | 
radcliffecardiology.com | Gi-Byoung Nam |Dipak Kotecha |Renato D. Lopes
ESC Congress 24 — AF screening with a wearable ECG device increases diagnosis by over 50% but did not significantly reduce hospitalisation rates for stroke.
